1. Home
  2. Recorded
  3. Course Details Page
Skip to content
eLearning on BoehringerOne
Visit BoehringerOne.com

Moving from now to the next in heart failure treatment: Insights from EMPEROR trials. Was this a breakthrough in HFpEF

Presenters

Prof. Javed Butler
Professor
Prof. Javed Butler
View Profile

  • 28 Mins 21 Secs

  • 2 CPD points upon completion (min pass rate 70%)

Start this course

Course details

The mechanism of action of an SGLT2 inhibitors has been studied to understand its impact on heart failure outcomes. However, previous trials have not shown improvement in outcomes for HFpEF patients until the EMPEROR Preserved trial, which showed positive results in for cardiovascular death, heart failure hospitalization, EGFR preservation, quality of life, and NYHA class improvement.